{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010514","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.927936+00:00","generated_at":"2026-05-21T06:20:09.623478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Abeona Q1 net loss $12M; ZEVASKYN approved Apr 28, PRV sold for $155M","bullets":["Net loss of $12.0M ($0.24/share) vs. $31.6M ($1.16/share) in Q1 2024; no revenue yet.","FDA approved ZEVASKYN on Apr 28; first QTC (Lurie Children’s) activated, first patient expected Q3 2025.","Entered asset purchase agreement to sell rare pediatric disease PRV for gross proceeds of $155M.","Cash and investments $84.5M at Mar 31, 2025; PRV proceeds to extend runway into early 2026.","~30 patients registered in Abeona Assist; value-based agreements with payers covering ~100M lives."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010514","json":"https://secwatch.observer/filing/0001641172-25-010514.json","markdown":"https://secwatch.observer/filing/0001641172-25-010514.md","text":"https://secwatch.observer/filing/0001641172-25-010514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/0001641172-25-010514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:20:09.623478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}